Etanercept and demyelinating disease in a patient with psoriasis

被引：41

作者：

Sukal, SA

Nadiminti, L

Granstein, RD

机构：

[1] Cornell Univ, Weill Med Coll, Dept Dermatol, New York Presbyterian Hosp, New York, NY 10021 USA

[2] Cornell Univ, Weill Med Coll, Dept Neurol, New York Presbyterian Hosp, New York, NY 10021 USA

来源：

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2006年 / 54卷 / 01期

关键词：

D O I：

10.1016/j.jaad.2005.05.039

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

The tumor necrosis factor-a antagonist (TNF-alpha) etanercept has been approved for the treatment of rheumatoid arthritis, juvenile rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and psoriasis. Earlier reports on the use of etanercept or infliximab in patients with rheumatoid arthritis, psoriatic arthritis, or juvenile rheumatoid arthritis suggested an increased risk of demyelinating disease. It is imperative that dermatologists have a keen awareness of this possible adverse event given the increased use of this class of drugs. We report a case of demyelinating disease occurring in a patient treated for psoriasis. The relation of TNF-alpha antagonist therapy to demyelinating disease/multiple sclerosis is explored. It is recommended that patients be diligently screened before starting TNF-alpha antagonist therapy and that vigilance for symptoms of demyelinating disease/multiple sclerosis be included in follow-up examinations during treatment with these drugs.

引用

页码：160 / 164

页数：5

共 43 条

[1] Oligodendrocyte apoptosis and primary demyelination induced by local TNF/p55TNF receptor signaling in the central nervous system of transgenic mice - Models for multiple sclerosis with primary oligodendrogliopathy [J].